CX-614

CX-614 is an ampakine compound created by Cortex Pharmaceuticals to assist in the study of the AMPA receptor. It has been investigated for its potential use in the treatment of Alzheimer's disease, attention deficit disorder, and schizophrenia.

Chemistry

CX-614 is an oxazoline compound that functions as a positive allosteric modulator of the AMPA receptor. It is structurally related to other ampakines such as CX-516 and CX-546.

Pharmacology

CX-614 has been shown to have a positive modulatory effect on the AMPA receptor. This effect is believed to enhance synaptic transmission, which could potentially improve cognitive function in individuals with disorders such as Alzheimer's disease, attention deficit disorder, and schizophrenia.

Clinical Trials

CX-614 has undergone phase II clinical trials for the treatment of Alzheimer's disease. However, the results of these trials have not been published, and the current status of CX-614's development is unclear.

See Also

• AMPA receptor
• Allosteric modulator
• Cortex Pharmaceuticals

References

CX-614 Resources
Need Help Finding a Doctor? Need help finding a doctor or specialist anywhere in the world? Explore our world directory. WikiMD's DocFinder can assist you in locating millions of physicians.	Medical Knowledge Access the latest research - Most recent articles Ongoing trials.

Translate to: East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski